4 - The names of the external study sites were added. 5 - The grant end date was updated. 6.4 - Language was amended for clarity. 15.2.3 15.3.4 - The storage recommendations for collected PBSCs were removed to allow for institutional variation. 15.3.5 - Reference to the collection of back -up PBSCs was removed since the cells, if successfully collected, will be administered to all Group B subjects. 16.2 - Langu age was amended to incorporate the infusion of the TTRNA - xALT product in accordance with SOP -UFBTIP -132. 17.4.3 - Language was amended to delineate what adverse events will be recorded. 19.3 - Language was amended to update the sterility testing location and type of testing. 19.4 - Language was amended to align with the Chemistry, Manufacturing, and Control language. STUDY R OAD MAP - PBSCs were added to the Consolidation or NMA Chemo time point to correlate with the narrative sections of the protocol. 30.1 - Reference to the SOP for the “Administration of ALT” was added. 20160303 1200 RB 3 3.1 3.2 4 8 21.1 21.6 25 25.1 - Key study personnel updated throughout protocol to reflect current individuals with assigned study duties. 17.4.3 - The duration of adverse event follow -up was modified for clarity. Re-MATC H Protocol Page 8 of 106 Version: 20180628 Summary of Protocol Changes Version Date Sections Revised Purpose 2.1 8 15.4 16.1 20.2 STUDY ROAD MAP - A plus or minus 1 day window was added to the day 4 assessments to provide scheduling flexibility. 2016050 5 1749 DAM 2.1 9 10.1 11.2 - Language regarding disease status eligibility was clarified . 20160908 1515 KW 31 - Single Patient -Specific Protocol (UF Site Only) was added as Addendum A to protocol 20170220 1100 KW Overall Document - Table of Contents updated for pagination - Footer updated with new version date. - Additional editorial, typographical and formatting changes have been made throughout the body of the protocol, along with minor changes for document consistency, all of which are tracked but not individually listed. 2.1 10.1 - Performance st atus age range modified to align with NIH criteria. 2.1 10.1 - Language regarding additional eligibility requirements updated to clarify applicability to both consolidation and NMA chemotherapy. 2 2.1 8 10.1 15.3.5 - Description of Group B regimen in these sections revised for consistency with other sections of the protocol. 2.1 8 - Language regarding localized relapse and disseminated disease clarified for consistent interpretation across sites. 2.1 15.2.3 15.3.4 - Minimum number of stem cells for harvest in Group A subjects specified in this section for clarity and consistency. 2.1 8 15.3.2 15.3.4 - Goal for stem cell harvest in Group B subjects added to this section for clarity and consistency. 2.1 8 - For subject safety and to minimize variabilit y, Group B subjects with no peripheral blood stem cells (PBSCs) for rescue will have NMA conditioning withheld and move to immunotherapy from salvage chemotherapy if all other eligibility has been met. Re-MATC H Protocol Page 9 of 106 Version: 20180628 2.1 8 15.4 - Timeframes and windows for follow -up visits clarified.